D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder

Summary

The purpose of the study is to conduct a double-blind, placebo-controlled study of D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic Disorder (BDD). Specifically, we intend to randomize 50 individuals with BDD to receive either DCS (n = 25) or placebo (n = 25) one hour prior to 8 of 10 behavior therapy sessions.

Timeline

Start

2008-11

Primary completion

2017-12

Completion

2018-08

Drugs

Indications